TY - JOUR
T1 - Continuous Production of Five Active Pharmaceutical Ingredients in Flexible Plug-and-Play Modules
T2 - A Demonstration Campaign
AU - Rogers, Luke
AU - Briggs, Naomi
AU - Achermann, Ramona
AU - Adamo, Andrea
AU - Azad, Mohammad
AU - Brancazio, David
AU - Capellades, Gerard
AU - Hammersmith, Gregory
AU - Hart, Travis
AU - Imbrogno, Joseph
AU - Kelly, Liam P.
AU - Liang, Guohua
AU - Neurohr, Clemence
AU - Rapp, Kersten
AU - Russell, M. Grace
AU - Salz, Carter
AU - Thomas, Dale A.
AU - Weimann, Lukas
AU - Jamison, Timothy F.
AU - Myerson, Allan S.
AU - Jensen, Klavs F.
N1 - Publisher Copyright:
©
PY - 2020/10/16
Y1 - 2020/10/16
N2 - Traditional pharmaceutical manufacturing is based on a complex supply chain that is vulnerable to spikes in demand and interruptions. Continuous pharmaceutical production in compact modules is a potential solution that allows for drug manufacturing when and where it is needed with significantly shorter lead times. As part of the Pharmacy on Demand (PoD) initiative, we demonstrate the potential for end-to-end manufacturing of multiple drug substances in reconfigurable devices, under common industrial constraints, and within a challenging manufacturing time frame. A new set of refrigerator-sized modules was constructed for the synthesis, isolation, and formulation of several drugs, with focus on achieving high manufacturing throughputs, and allowing for the production of pharmaceutical tablets. Their operation is demonstrated with the synthesis and formulation of USP-compliant tablets of diazepam, diphenhydramine hydrochloride, and ciprofloxacin hydrochloride, as well as liquid formulations of lidocaine hydrochloride and atropine sulfate.
AB - Traditional pharmaceutical manufacturing is based on a complex supply chain that is vulnerable to spikes in demand and interruptions. Continuous pharmaceutical production in compact modules is a potential solution that allows for drug manufacturing when and where it is needed with significantly shorter lead times. As part of the Pharmacy on Demand (PoD) initiative, we demonstrate the potential for end-to-end manufacturing of multiple drug substances in reconfigurable devices, under common industrial constraints, and within a challenging manufacturing time frame. A new set of refrigerator-sized modules was constructed for the synthesis, isolation, and formulation of several drugs, with focus on achieving high manufacturing throughputs, and allowing for the production of pharmaceutical tablets. Their operation is demonstrated with the synthesis and formulation of USP-compliant tablets of diazepam, diphenhydramine hydrochloride, and ciprofloxacin hydrochloride, as well as liquid formulations of lidocaine hydrochloride and atropine sulfate.
UR - http://www.scopus.com/inward/record.url?scp=85096304616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096304616&partnerID=8YFLogxK
U2 - 10.1021/acs.oprd.0c00208
DO - 10.1021/acs.oprd.0c00208
M3 - Article
AN - SCOPUS:85096304616
SN - 1083-6160
VL - 24
SP - 2183
EP - 2196
JO - Organic Process Research and Development
JF - Organic Process Research and Development
IS - 10
ER -